Effect of n-3 Polyunsaturated Fatty Acids on Regression of Coronary Atherosclerosis in Statin Treated Patients Undergoing Percutaneous Coronary Intervention

• Published in: Korean circulation journal Vol. 46; no. 4; pp. 481 - 489
• Main Authors: Ahn, Jinhee, Park, Seo Kwang, Park, Tae Sik, Kim, Jin Hee, Yun, Eunyoung, Kim, Sang-Pil, Lee, Hye Won, Oh, Jun-Hyok, Choi, Jung Hyun, Cha, Kwang Soo, Hong, Taek Jong, Lee, Sang Yeoup, Lee, Han Cheol
• Format: Journal Article
• Language: English
• Published: Korea (South) The Korean Society of Cardiology 01.07.2016; 대한심장학회
• Subjects: Original; 내과학; Statin; Coronary artery disease; Atherosclerosis; n-3 polyunsaturated fatty acids
• ISSN: 1738-5520; 1738-5555
• DOI: 10.4070/kcj.2016.46.4.481

Statins remain the mainstay of secondary coronary artery disease (CAD) prevention, but n-3 polyunsaturated fatty acids (ω-3 PUFA) display biological effects that may also reduce the risk of atherosclerosis and CAD. However, data on the possible antiatherosclerotic benefits of adding ω-3 PUFA to statin therapy are limited. This study aimed to investigate the potential additive effects of ω-3 PUFA on regression of atherosclerosis in CAD patients receiving statin therapy and stent implantation. Seventy-four CAD patients undergoing percutaneous coronary intervention (PCI) with stent implantation were enrolled, prescribed statins, and randomly assigned to two groups: n-3 group (ω-3 PUFA 3 g/day, n=38) or placebo group (placebo, n=36). All patients completed the study follow-up consisting of an intravascular ultrasound at baseline and at 12 months. There was no difference in the baseline characteristics and distribution of other medications. No significant differences were observed in primary endpoints, including changes in atheroma volume index (-12.65% vs. -8.51%, p=0.768) and percent atheroma volume (-4.36% vs. -9.98%, p=0.526), and in secondary endpoints including a change in neointimal volume index (7.84 vs. 4.94 mm(3)/mm, p=0.087). ω-3 PUFA had no definite additional effect on the regression of coronary atherosclerosis when added to statin in CAD patients undergoing PCI.